PriceTargets.com logo

Amneal Pharmaceuticals - AMRX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $3.67
  • Forecasted Upside: 175.69%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.33 As of 03/24/2023 01:00 AM ET
▲ +0.02 (1.53%)

This chart shows the closing price for AMRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Amneal Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AMRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AMRX

Analyst Price Target is $3.67
▲ +175.69% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Amneal Pharmaceuticals in the last 3 months. The average price target is $3.67, with a high forecast of $4.00 and a low forecast of $3.00. The average price target represents a 175.69% upside from the last price of $1.33.

This chart shows the closing price for AMRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Amneal Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/1/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/30/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/30/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/28/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/26/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/25/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/23/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2023

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/10/2023BarclaysLower TargetOverweight$7.00 ➝ $4.00Low
3/3/2023The Goldman Sachs GroupLower TargetBuy$3.50 ➝ $3.00Low
3/3/2023BMO Capital MarketsLower TargetMarket Perform$5.00 ➝ $4.00Low
8/8/2022The Goldman Sachs GroupLower TargetBuy$4.50 ➝ $4.00Low
4/28/2022BarclaysLower Target$8.00 ➝ $7.00Low
4/14/2021GuggenheimBoost TargetBuy$6.50 ➝ $8.00Low
3/19/2021Piper SandlerBoost TargetOverweight$7.00 ➝ $9.00High
3/8/2021The Goldman Sachs GroupUpgradeSell ➝ Buy$4.00 ➝ $6.50High
3/1/2021BarclaysBoost TargetOverweight$6.00 ➝ $8.00Low
12/15/2020SVB LeerinkReiterated RatingHold$5.50High
12/14/2020GuggenheimUpgradeNeutral ➝ Buy$5.50Low
12/14/2020BarclaysUpgradeEqual Weight ➝ Overweight$4.50 ➝ $6.00Low
11/9/2020SVB LeerinkLower TargetMarket Perform$6.00 ➝ $5.50Medium
10/9/2020Piper SandlerBoost TargetOverweight$5.00 ➝ $6.00Medium
7/27/2020The Goldman Sachs GroupInitiated CoverageSell$4.00High
5/13/2020SunTrust BanksBoost TargetBuy$4.00 ➝ $5.00Low
5/12/2020SVB LeerinkBoost TargetMarket Perform$3.00 ➝ $4.00High
5/12/2020GuggenheimUpgradeSell ➝ NeutralHigh
4/16/2020Royal Bank of CanadaReiterated RatingHold$4.00Medium
4/2/2020Morgan StanleyLower TargetEqual Weight$5.00 ➝ $3.00Low
2/27/2020SunTrust BanksLower TargetBuy$6.00 ➝ $5.00High
1/2/2020Royal Bank of CanadaBoost TargetSector Perform$3.00 ➝ $4.00Low
12/13/2019Piper Jaffray CompaniesBoost TargetOverweight$4.00 ➝ $7.00Medium
12/12/2019BTIG ResearchBoost TargetBuy$5.00 ➝ $7.00High
12/12/2019Raymond JamesDowngradeOutperform ➝ Market PerformHigh
11/12/2019JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightHigh
9/12/2019GuggenheimInitiated CoverageSell$2.50High
8/6/2019BMO Capital MarketsLower TargetMarket Perform$6.00 ➝ $5.00High
8/6/2019SunTrust BanksReiterated RatingBuy$5.00High
7/22/2019SVB LeerinkUpgradeMarket Perform ➝ Outperform$11.00 ➝ $5.00Low
7/11/2019BarclaysSet TargetHold$5.00High
7/11/2019SunTrust BanksLower TargetBuy$16.00 ➝ $9.00High
7/11/2019Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$11.00 ➝ $6.00High
7/10/2019Raymond JamesDowngradeStrong-Buy ➝ Outperform$13.00 ➝ $8.50High
7/8/2019Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$11.00Medium
6/12/2019Cantor FitzgeraldLower TargetOverweight$35.00 ➝ $14.00Low
6/11/2019BarclaysInitiated CoverageEqual Weight ➝ Equal Weight$9.00High
5/21/2019Raymond JamesUpgradeMarket Perform ➝ Strong-Buy$13.00High
5/10/2019BMO Capital MarketsLower TargetMarket Perform$14.00 ➝ $13.00High
3/19/2019SunTrust BanksInitiated CoverageBuy ➝ Buy$16.00Low
3/8/2019SVB LeerinkDowngradeOutperform ➝ Market Perform$16.00 ➝ $12.00Low
2/28/2019Cantor FitzgeraldReiterated RatingBuy$35.00Low
1/3/2019SVB LeerinkReiterated RatingOutperform$25.00 ➝ $19.00High
12/14/2018Morgan StanleyDowngradeOverweight ➝ Equal Weight$24.00 ➝ $18.00Medium
10/16/2018SunTrust BanksDowngradeBuy ➝ Hold$15.00Low
10/3/2018Morgan StanleyLower TargetOverweight ➝ Overweight$26.00 ➝ $24.00Medium
8/22/2018B. RileyBoost TargetBuy ➝ Buy$26.00 ➝ $28.00Low
8/13/2018Royal Bank of CanadaUpgradeSector Perform ➝ OutperformHigh
8/10/2018BMO Capital MarketsBoost TargetMarket Perform ➝ Market Perform$19.00 ➝ $20.00Low
8/9/2018Cantor FitzgeraldReiterated RatingBuy$35.00Low
7/23/2018Morgan StanleyInitiated CoverageOverweight$22.00High
6/22/2018B. RileyInitiated CoverageBuy$26.00High
5/18/2018GuggenheimReiterated RatingHoldLow
5/18/2018JPMorgan Chase & Co.Initiated CoverageNeutral$18.00Medium
5/9/2018Deutsche Bank AktiengesellschaftInitiated CoverageBuyN/A
(Data available from 3/26/2018 forward)

News Sentiment Rating

0.31 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
8/28/2022
  • 5 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2022
  • 3 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2022
  • 3 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2022
  • 4 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2022
  • 3 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
1/25/2023
  • 5 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2023
  • 2 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2023

Current Sentiment

  • 2 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Amneal Pharmaceuticals logo
Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generic, Specialty and AvKARE Segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The AvKARE segment focuses on pharmaceuticals, medical and surgical products, and services primarily to governmental agencies. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.
Read More

Today's Range

Now: $1.33
Low: $1.28
High: $1.34

50 Day Range

MA: $2.02
Low: $1.31
High: $2.70

52 Week Range

Now: $1.33
Low: $1.28
High: $4.60

Volume

578,403 shs

Average Volume

1,180,421 shs

Market Capitalization

$403.81 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.37

Frequently Asked Questions

What sell-side analysts currently cover shares of Amneal Pharmaceuticals?

The following equities research analysts have issued research reports on Amneal Pharmaceuticals in the last year: Barclays PLC, BMO Capital Markets, StockNews.com, The Goldman Sachs Group, Inc., and TheStreet.
View the latest analyst ratings for AMRX.

What is the current price target for Amneal Pharmaceuticals?

3 Wall Street analysts have set twelve-month price targets for Amneal Pharmaceuticals in the last year. Their average twelve-month price target is $3.67, suggesting a possible upside of 175.7%. Barclays PLC has the highest price target set, predicting AMRX will reach $4.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $3.00 for Amneal Pharmaceuticals in the next year.
View the latest price targets for AMRX.

What is the current consensus analyst rating for Amneal Pharmaceuticals?

Amneal Pharmaceuticals currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AMRX will outperform the market and that investors should add to their positions of Amneal Pharmaceuticals.
View the latest ratings for AMRX.

What other companies compete with Amneal Pharmaceuticals?

Other companies that are similar to Amneal Pharmaceuticals include Repare Therapeutics, Nurix Therapeutics, Edgewise Therapeutics, Emergent BioSolutions and Lexicon Pharmaceuticals. Learn More about companies similar to Amneal Pharmaceuticals.

How do I contact Amneal Pharmaceuticals' investor relations team?

Amneal Pharmaceuticals' physical mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The company's listed phone number is (908) 947-3120 and its investor relations email address is [email protected] The official website for Amneal Pharmaceuticals is www.amneal.com. Learn More about contacing Amneal Pharmaceuticals investor relations.